thalidomide has been researched along with Gait Disorders, Animal in 1 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Lenalidomide is a potent immunomodulatory agent, with the ability to down-regulate pro-inflammatory cytokines and up-regulate anti-inflammatory cytokines." | 5.35 | Lenalidomide (Revlimid) administration at symptom onset is neuroprotective in a mouse model of amyotrophic lateral sclerosis. ( Beal, MF; Calingasan, NY; Hensley, K; Kiaei, M; Neymotin, A; Petri, S; Schafer, P; Stewart, C; Wille, E, 2009) |
| "Lenalidomide is a potent immunomodulatory agent, with the ability to down-regulate pro-inflammatory cytokines and up-regulate anti-inflammatory cytokines." | 1.35 | Lenalidomide (Revlimid) administration at symptom onset is neuroprotective in a mouse model of amyotrophic lateral sclerosis. ( Beal, MF; Calingasan, NY; Hensley, K; Kiaei, M; Neymotin, A; Petri, S; Schafer, P; Stewart, C; Wille, E, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Neymotin, A | 1 |
| Petri, S | 1 |
| Calingasan, NY | 1 |
| Wille, E | 1 |
| Schafer, P | 1 |
| Stewart, C | 1 |
| Hensley, K | 1 |
| Beal, MF | 1 |
| Kiaei, M | 1 |
1 other study available for thalidomide and Gait Disorders, Animal
| Article | Year |
|---|---|
Lenalidomide (Revlimid) administration at symptom onset is neuroprotective in a mouse model of amyotrophic lateral sclerosis.
Topics: Amyotrophic Lateral Sclerosis; Animals; Anti-Inflammatory Agents; Antineoplastic Agents; Body Weight | 2009 |